AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com2024-11-16

Accounts Payable Dispute: $4.9 million in accounts payable currently under dispute and negotiation. Insurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483567515?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ELG_R7DzGcBp5NY2qCM2MQ--~B/aD0yOTE7dz0yOTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0d78dd1b3586d1c1f9b210f702c00c14","is_english":true,"pubTime":"2024-11-16 15:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483567515","market":"us","top_or_hot":-1,"title":"AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...","media":"GuruFocus.com","content":"<div>\n<p>Accounts Payable Dispute: $4.9 million in accounts payable currently under dispute and negotiation.\nInsurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aim-immunotech-inc-aim-q3-070150154.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 15:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aim-immunotech-inc-aim-q3-070150154.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Accounts Payable Dispute: $4.9 million in accounts payable currently under dispute and negotiation.\nInsurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aim-immunotech-inc-aim-q3-070150154.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIM","symbol_name":"AIM ImmunoTech Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/aim-immunotech-inc-aim-q3-070150154.html","article_id":"2483567515","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ELG_R7DzGcBp5NY2qCM2MQ--~B/aD0yOTE7dz0yOTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0d78dd1b3586d1c1f9b210f702c00c14"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483567515","pubTimestamp":1731740510,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Accounts Payable Dispute: $4.9 million in accounts payable currently under dispute and negotiation.Insurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not yet paid.R&D Investment: Over $200,000 invested in R&D experiments to optimize Ampligen production.Cost Savings: Estimated $2 million savings in method transfer and validation process, with future cost reductions of about $200,000 per batch of Ampligen.GuruFocus has detected 6 Warning Signs with AIM.For the complete transcript of the earnings call, please refer to the full earnings call transcript.AIM ImmunoTech Inc  reported positive preliminary data from the Phase Ib/II DURIPANC study, showing promising results in treating late-stage metastatic pancreatic cancer.AIM ImmunoTech Inc  is currently disputing $4.9 million in accounts payable, which could impact its financial stability.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AIM":"AIM ImmunoTech Inc"},"translate_title":"AIM ImmunoTech Inc(AIM)2024年第三季度收益看涨期权亮点：金融领域的战略进展...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":1},"content_text":"Accounts Payable Dispute: $4.9 million in accounts payable currently under dispute and negotiation.\nInsurance Coverage Issue: $2.5 million secondary layer of coverage from a D&O insurance company not yet paid.\nR&D Investment: Over $200,000 invested in R&D experiments to optimize Ampligen production.\nCost Savings: Estimated $2 million savings in method transfer and validation process, with future cost reductions of about $200,000 per batch of Ampligen.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with AIM.\n\nRelease Date: November 15, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nAIM ImmunoTech Inc (AIM) reported positive preliminary data from the Phase Ib/II DURIPANC study, showing promising results in treating late-stage metastatic pancreatic cancer.\nThe company announced statistically significant data supporting Ampligen as a potential therapeutic for moderate to severe post-COVID conditions of fatigue.\nAIM ImmunoTech Inc (AIM) continues to expand its intellectual property portfolio, including a new patent for Ampligen in the treatment of endometriosis.\nThe company has optimized its manufacturing process, reducing production time by approximately 40% and saving an estimated $2 million in costs.\nAIM ImmunoTech Inc (AIM) is actively pursuing partnerships and commercialization opportunities, potentially increasing its attractiveness for big pharma collaborations.\n\n Negative Points \n\nAIM ImmunoTech Inc (AIM) is currently disputing $4.9 million in accounts payable, which could impact its financial stability.\nThe company is facing challenges with one of its D&O insurance companies, which has not paid a $2.5 million secondary layer of coverage.\nThere are ongoing concerns about the company's going concern status and stockholder equity issues.\nA group of activist investors is attempting to take control of the board, which could lead to instability and potential depletion of cash reserves.\nThe company encountered last-minute screen failures in its DURIPANC study, requiring additional patient enrollment to gather necessary data.\n\n Q & A Highlights \nQ: Could you provide additional details on the next steps for the long COVID program and potential future studies? A: Thomas Equels, CEO, explained that they are using recent data to formulate a profile for inclusion in the next trial, focusing on moderate to severe cases. Dr. Christopher McAleer, Chief Scientific Officer, added that if Ampligen is chosen for the RECOVER TLC program, the NIH will drive the clinical design. If not, they plan a Phase II/III trial targeting severe patients with specific biomarkers.\nQ: How much does it cost to produce a batch of Ampligen, and are there opportunities to reduce this cost further? A: Thomas Equels, CEO, mentioned ongoing efforts to improve manufacturing efficiencies. Dr. Christopher McAleer, Chief Scientific Officer, noted that recent process optimizations have reduced polymer production costs from $400,000 to $200,000 per batch. They aim to further reduce costs by transitioning to a continuous flow process, potentially lowering costs by 60-70%.\nQ: What progress has been made in the pancreatic cancer trials, specifically the DURIPANC study? A: Dr. Christopher McAleer, Chief Scientific Officer, reported that the DURIPANC study is progressing well, with the 200-milligram dose deemed safe and moving to 400-milligram dosing. Preliminary data shows promising progression-free survival improvements, with a final patient enrollment expected by year-end and Phase II anticipated in Q1 2025.\nQ: Can you elaborate on the ovarian cancer trial and its current status? A: Dr. Christopher McAleer, Chief Scientific Officer, stated that the trial combining Ampligen, cisplatin, and pembrolizumab for advanced recurrent ovarian cancer is being downsized due to impressive response rates. Enrollment is wrapping up, with a manuscript submission planned by year-end.\nQ: What are the financial challenges AIM ImmunoTech is currently facing? A: Thomas Equels, CEO, highlighted disputes over $4.9 million in accounts payable and a $2.5 million insurance coverage issue. These are significant factors affecting the company's financial health, and efforts are underway to resolve them positively.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483567515"}